Vertex Pharmaceuticals (NASDAQ:VRTX) Given “Hold” Rating at Needham & Company LLC
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. Other equities analysts have also issued reports about the stock.
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
Zacks.com on MSN3d
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesVertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by Royal Bank of Canada from $402.00 to $407.00 in a research note issued to investors on Tuesday,Benzinga reports.
EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...
CIEN, GIS, MDLZ, CRWD, MRK, NOW, VRTX, HPE May Stock Recovery as Economy Sends Mixed Signals The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback